Article
Modulatory effects of metformin on mutagenicity and epithelial tumor incidence in doxorubicin-treated Drosophila melanogaster.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association - 1 Aug 2017
Oliveira Victor Constante, Constante Sarah Alves Rodrigues, Orsolin Priscila Capelari, Nepomuceno Júlio César, de Rezende Alexandre Azenha Alves, Spanó Mário Antônio
Abstract excerpt
Metformin (MET) is an anti-diabetic drug used to prevent hepatic glucose release and increase tissue insulin sensitivity. Diabetic cancer patients are on additional therapy with anticancer drugs. Doxorubicin (DXR) is a cancer chemotherapeutic agent that interferes with the topoisomerase II enzyme and generates free radicals. MET (2.5, 5, 10, 25 or 50 mM) alone was examined for mutagenicity, recombinogenicity and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.